The value of putaminal diffusion imaging versus 18-fluorodeoxyglucose positron emission tomography for the differential diagnosis of the Parkinson variant of multiple system atrophy

Movement Disorders

Volumn 29, Issue 3, 2014, Pages 380-387

  Baudrexel, Simon ^a   Seifried, Carola ^a   Penndorf, Bianca ^a   Klein, Johannes C ^a   Middendorp, Marcus ^a   Steinmetz, Helmuth ^a   Grünwald, Frank ^a   Hilker, Rüdiger ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Diffusion weighted imaging; Mean diffusivity; Multiple system atrophy; PET; Volumetry

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; ENERGY METABOLISM; FEMALE; HUMAN; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARKINSON DISEASE; PARKINSON VARIANT OF MULTIPLE SYSTEM ATROPHY; PARKINSONISM; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PUTAMEN; PUTAMINAL DIFFUSION WEIGHTED IMAGING; RECEIVER OPERATING CHARACTERISTIC; SHY DRAGER SYNDROME; UNIFIED PARKINSON DISEASE RATING SCALE; DIAGNOSTIC USE; MIDDLE AGED; PATHOLOGY; PROCEDURES; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; PUTAMEN;

EID: 84896128815     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25749     Document Type: Article

References (38)

1. Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004;3:93-103.
2. Ozawa T, Paviour D, Quinn NP, et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 2004;127:2657-2671.
3. Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 1994;117:235-243.
4. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997;12:133-147.
5. Litvan I, Goetz CG, Jankovic J, et al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol 1997;54:937-944.
6. Brooks DJ, Seppi K. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 2009;24:949-964.
7. Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005;26:912-921.
8. Eidelberg D, Takikawa S, Moeller JR, et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol 1993;33:518-527.
9. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670-676.
10. Lee EA, Cho HI, Kim SS, Lee WY. Comparison of magnetic resonance imaging in subtypes of multiple system atrophy. Parkinsonism Relat Disord 2004;10:363-368.
11. Pellecchia MT, Barone P, Mollica C, et al. Diffusion-weighted imaging in multiple system atrophy: a comparison between clinical subtypes. Mov Disord 2009;24:689-696.
12. Schocke MF, Seppi K, Esterhammer R, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 2002;58:575-580.
13. Tsukamoto K, Matsusue E, Kanasaki Y, et al. Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson's disease: evaluation by 3.0-T MR imaging. Neuroradiology 2012;54:947-955.
14. Ito M, Watanabe H, Kawai Y, et al. Usefulness of combined fractional anisotropy and apparent diffusion coefficient values for detection of involvement in multiple system atrophy. J Neurol Neurosurg Psychiatry 2007;78:722-728.
15. Kwon KY, Choi CG, Kim JS, Lee MC, Chung SJ. Diagnostic value of brain MRI and 18F-FDG PET in the differentiation of Parkinsonian-type multiple system atrophy from Parkinson's disease. Eur J Neurol 2008;15:1043-1049.
16. Nicoletti G, Lodi R, Condino F, et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 2006;129:2679-2687.
17. Tang CC, Poston KL, Eckert T, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 2010;9:149-158.
18. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
19. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop. Neurology 1996;47:1-9.
20. Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005;128:1247-1258.
21. Preibisch C, Deichmann R. Influence of RF spoiling on the stability and accuracy of T1 mapping based on spoiled FLASH with varying flip angles. Magn Reson Med 2009;61:125-135.
22. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994;14:783-801.
23. Ma Y, Tang C, Moeller JR, Eidelberg D. Abnormal regional brain function in Parkinson's disease: truth or fiction? Neuroimage 2009;45:260-266.
24. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77.
25. Fearnley JM, Lees AJ. Striatonigral degeneration. A clinicopathological study. Brain 1990;113:1823-1842.
26. Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry 2002;73:517-523.
27. Seppi K, Schocke MF, Prennschuetz-Schuetzenau K, et al. Topography of putaminal degeneration in multiple system atrophy: a diffusion magnetic resonance study. Mov Disord 2006;21:847-852.
28. Le Bihan D, Mangin JF, Poupon C, et al. Diffusion tensor imaging: concepts and applications. J Magn Reson Imaging 2001;13:534-546.
29. Gjedde A, Marrett S, Vafaee M. Oxidative and nonoxidative metabolism of excited neurons and astrocytes. J Cereb Blood Flow Metab 2002;22:1-14.
30. Seppi K, Schocke MF, Mair KJ, et al. Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study. Neuroimage 2006;31:240-245.
31. Antonini A, Leenders KL, Vontobel P, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997;120:2187-2195.
32. Poston KL, Tang CC, Eckert T, et al. Network correlates of disease severity in multiple system atrophy. Neurology 2012;78:1237-1244.
33. Alexander AL, Lee JE, Wu YC, Field AS. Comparison of diffusion tensor imaging measurements at 3.0 T versus 1.5 T with and without parallel imaging. Neuroimaging Clin N Am 2006;16:299-309, xi.
34. Seppi K, Schocke MF, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003;60:922-927.
35. Schulz JB, Skalej M, Wedekind D, et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1999;45:65-74.
36. Ricard D, Taillia H, Renard JL. Brain damage from anticancer treatments in adults. Curr Opin Oncol 2009;21:559-565.
37. Tashiro M, Kubota K, Itoh M, et al. Regional cerebral glucose metabolism of patients with malignant diseases in different clinical phases. Med Sci Monit 2001;7:226-232.
38. Eggers C, Hilker R, Burghaus L, Schumacher B, Heiss WD. High resolution positron emission tomography demonstrates basal ganglia dysfunction in early Parkinson's disease. J Neurol Sci 2009;276:27-30.